Association between very low PTH levels and poor survival rates in haemodialysis patients: Results from the French ARNOS cohort

Nephron - Clinical Practice

Volumn 118, Issue 2, 2011, Pages

  Jean, G ^a   Lataillade, D ^b   Genet, L ^c   Legrand, E ^d   Kuentz, F ^e   Moreau Gaudry, X ^e   Fouque, D ^c  

^a Centre de Rein Artificiel de Tassin   (France)

^b Centre de Néphrologie du Mont Blanc   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CENTRE HOSPITALIER   (France)

^e AGDUC   (France)

Author keywords

Bone disease; Haemodialysis; Parathyroid hormone; Survival rates

Indexed keywords

ALBUMIN; ALFACALCIDOL; CALCIUM; CALCIUM CARBONATE; CINACALCET; DIALYSATE CALCIUM; PARATHYROID HORMONE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; ENDOCRINE DISEASE; FEMALE; FRANCE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INTAKE; SURVIVAL RATE; VERY LOW PARATHYROID HORMONE LEVEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DISEASES, METABOLIC; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS; SURVIVAL RATE;

EID: 78650243055     PISSN: 16602110     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000321642     Document Type: Article

References (35)

1. Souberbielle JC, Roth H, Fouque DP: Parathyroid hormone measurement in CKD. Kidney Int 2010; 77: 93-100.
2. KDIGO CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 113:S1-S130.
3. Ballanti P, Wedard BM, Bonucci E: Frequency of adynamic bone disease and aluminum storage in Italian uraemic patients - retrospective analysis of 1,429 iliac crest biopsies. Nephrol Dial Transplant 1996; 11: 663-667.
4. Kazama JJ, Omori K, Yamamoto S, Ito Y, Maruyama H, Narita I, Gejyo F, Iwasaki Y, Fukagawa M: Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism. Ther Apher Dial 2006; 10: 262-266. (Pubitemid 43979297)
5. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A: A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58: 753-761. (Pubitemid 30620025)
6. Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A: Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996; 11: 2430-2438. (Pubitemid 27033776)
7. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-631.
8. Lorenzo V, Martin M, Rufino M, Jimenez A, Malo AM, Sanchez E, Hernandez D, Rodriguez M, Torres A: Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients. Am J Kidney Dis 2001; 37: 1260-1266. (Pubitemid 32525164)
9. Holgado R, Haire H, Ross D, Sprague S, Pahl M, Jara A, Martin-Malo A, Rodriguez M, Almaden Y, Felsenfeld AJ: Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res 2000; 15: 927-935. (Pubitemid 30233417)
10. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951. (Pubitemid 38822076)
11. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160-1166. (Pubitemid 24319957)
12. Couttenye MM, D'Haese PC, Deng JT, Van Hoof VO, Verpooten GA, De Broe ME: High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 1997; 12: 2144-2150. (Pubitemid 27423256)
13. Malluche HH, Monier-Faugere MC: Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 1992; 38:S62-S67.
14. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC: Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827-1835.
15. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861. (Pubitemid 24272045)
16. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
17. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780. (Pubitemid 44215354)
18. Eknoyan G, Levin A, Levin NW: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: 1-201.
19. Urena P, De Vernejoul MC: Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141-2156. (Pubitemid 29256470)
20. Barreto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB: K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777. (Pubitemid 351323258)
21. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH: Improved assessment of bone turnover by the PTH-(1-84)/large c-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60: 1460-1468. (Pubitemid 32960040)
22. Saleh FN, Schirmer H, Sundsfjord J, Jorde R: Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003; 24: 2054-2060. (Pubitemid 37420453)
23. Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, Baulieu EE: Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 2001; 86: 3086-3090. (Pubitemid 32673470)
24. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P: Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 2006; 70: 345-350. (Pubitemid 44086584)
25. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM: PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149-156. (Pubitemid 41828277)
26. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779. (Pubitemid 38294808)
27. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021. (Pubitemid 30410374)
28. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740. (Pubitemid 37098542)
29. Andress DL: Adynamic bone in patients with chronic kidney disease. Kidney Int 2008; 73: 1345-1354. (Pubitemid 351770492)
30. Haris A, Sherrard DJ, Hercz G: Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int 2006; 70: 931-937. (Pubitemid 44285971)
31. Galassi A, Spiegel DM, Bellasi A, Block GA, Raggi P: Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transplant 2006; 21: 3215-3222. (Pubitemid 44567097)
32. Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH, on behalf of the Sevelamer Study G: Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19: 405-412. (Pubitemid 351240662)
33. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252. (Pubitemid 34754068)
34. Lorenzo Sellares V, Torres Ramirez A: Management of hyperphosphataemia in dialysis patients: Role of phosphate binders in the elderly. Drugs Aging 2004; 21: 153-165. (Pubitemid 38340001)
35. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: The dialysis outcomes and practice patterns study. Kidney Int 2005; 67: 1179-1187. (Pubitemid 41623345)